Artificial intelligence has yet to deliver on the most challenging aspect of drug development — finding new molecules that lead to major medical advances — but it is already streamlining less glamorous parts of the process, industry executives say.
AI is helping find participants and sites for clinical trials and drafting documents for regulators, shaving weeks off these labor-intensive processes, seven large drugmakers and six smaller biotech companies said at the recent JP Morgan Healthcare Conference.
It can take a decade and $2 billion…
